Ventipulmin description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Ventipulmin

Boehringer Ingelheim Vetmedica, Inc.
Boehringer Ingelheim Vetmedica, Inc.

®


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

NADA 140-973, Approved by FDA

For oral use in horses only

Caution:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Caution:

Federal law prohibits the extralabel use of this drug in food animals.

Each mL contains:

Clenbuterol HCl 72.5 mcg

Description:

Clenbuterol (4-amino-alpha-[(tert-butylamino) methyl]-3, 5-dichlorobenzyl alcohol hydrochloride) is a beta-2-adrenergic agonist which provides bronchodilating properties as well as other effects, with minimum effect on the cardiovascular system. It is provided as a colorless, palatable syrup. Ventipulmin Syrup (clenbuterol hydrochloride) is antagonized by beta-adrenergic blocking agents.

Indications:

Ventipulmin Syrup (clenbuterol hydrochloride) is indicated for the management of horses affected with airway obstruction, such as occurs in chronic obstructive pulmonary disease (COPD).

Contraindications:

Ventipulmin Syrup antagonizes the effects of prostaglandin F2 alpha and oxytocin. Ventipulmin Syrup should not be used in pregnant mares near term. Because tachycardia may occur, Ventipulmin Syrup should not be used in horses suspected of having cardiovascular impairment.

Warning:

The effect on reproduction in breeding stallions and brood mares has not been determined. Treatment starting with dosages higher than the initial dose is not recommended.

Human Warnings:

Not for human use. Do not use in horses intended for human consumption. Keep out of the reach of children. In case of accidental ingestion, contact a physician immediately. Ingestion of Ventipulmin Syrup may cause undesirable reactions. Clenbuterol, like other beta adrenergic agonists, can produce significant cardiovascular effects in some people as evidenced by elevated pulse rate, blood pressure changes and/or ECG changes.

Dosage and Administration:

Administer orally twice a day (b.i.d.). Initial dose is 0.5 mL/100 lbs body weight (0.8 mcg/kg) twice daily.

Dosage Schedule:

Initial dosage: administer 0.5 mL/100 lbs (0.8 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 1.0 mL/100 lbs (1.6 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 1.5 mL/100 lbs (2.4 mcg/kg) for 3 days (6 treatments);

If no improvement, administer 2.0 mL/100 lbs (3.2 mcg/kg) for 3 days (6 treatments);

If no improvement, horse is non-responsive to clenbuterol and treatment should be discontinued.

Recommended duration of treatment at effective dose is 30 days. At the end of this 30-day treatment period, drug should be withdrawn to determine recurrence of signs. If signs return, the 30-day treatment regimen may be repeated. If repeating treatment, the step-wise dosage schedule should be repeated.

Directions for Administration:

Remove safety cap and seal; replace with enclosed plastic dispensing cap. Remove cover from dispensing tip and connect syringe (without needle). Draw out appropriate volume of Ventipulmin Syrup. Administer orally to the horse. Replace cover on dispensing tip to prevent leakage.

Dosage Calculation Chart

Lbs. Body

Weight

mL/treatment

at 0.5 mL/100#

(0.8 mcg/kg)

mL/treatment

at 1.0 mL/100#

(1.6 mcg/kg)

mL/treatment

at 1.5 mL/100#

(2.4 mcg/kg)

mL/treatment

at 2.0 mL/100#

(3.2 mcg/kg)

500

600

700

800

900

1000

1100

1200

1300

1400

1500

1600

1700

1800

2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

5.0

6.0

7.0

8.0

9.0

10.0

11.0

12.0

13.0

14.0

15.0

16.0

17.0

18.0

7.5

9.0

10.5

12.0

13.5

15.0

16.5

18.0

19.5

21.0

22.5

24.0

25.5

27.0

10.0

12.0

14.0

16.0

18.0

20.0

22.0

24.0

26.0

28.0

30.0

32.0

34.0

36.0

Administer two treatments per day.

Precaution:

The safety cap should be placed on the bottle when not in use.

Side Effects:

Mild sweating, muscle tremor, restlessness, urticaria and tachycardia may be observed in some horses during the first few days of treatment. May cause elevated creatine kinase (CK) serum levels. Ataxia was observed in 3 out of 239 horses (1.3%) in clinical studies. To report suspected adverse reactions, to obtain a Material Safety Data Sheet (MSDS), or for technical assistance, call 1-866-638-2226.

How Supplied:

Ventipulmin Syrup is available in 100 mL, 330 mL and 460 mL plastic bottles containing 72.5 mcg clenbuterol HCl per mL.

NDC 0010-3017-02 - 100 mL
NDC 0010-3017-03 - 330 mL
NDC 0010-3017-04 - 460 mL

Storage:

Store at or below 25°C (77°F). Avoid freezing.

Ventipulmin is a registered trademark of Boehringer Ingelheim Vetmedica GmbH.

Manufactured for:
Boehringer Ingelheim Vetmedica, Inc.
St. Joseph, MO 64506 U.S.A.

301721-03

090330770/1

330 mL Container Label

330 mL Display Carton – Front, Top and Side Panel

330 mL Display Carton – Back and Side Panel

Ventipulmin

clenbuterol SYRUP

Product Information

Product Type Prescription animal drug label Item Code (Source) NDC:0010-3017
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
CLENBUTEROL HYDROCHLORIDE CLENBUTEROL 0.0725 mg

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 100 in 1 BOTTLE, PLASTIC
2 330 in 1 BOTTLE, PLASTIC
3 460 in 1 BOTTLE, PLASTIC
4 NDC:0010-3017-04 1 in 1 CARTON

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NADA NADA140973 2011-01-12


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.